The LA Allergy Society’s Fall Symposium will be live this year.
September 24, 2022 – The Skirball Cultural Center, Los Angeles, CA
Members, non-members and fellows can register here.
We welcome Industry professionals to this meeting. Register here.
Exhibitors are welcome. Register here.
The Los Angeles Society of Allergy, Asthma, and Clinical Immunology (LASAACI) is a CME educational meeting jointly provided by the American College of Allergy, Asthma and Immunology, and the LASAACI. The 2022 program is a four-hour event with speakers covering the topics of EoE, AERD, and MCAS. The LASAACI Faculty are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content.
Practicing allergists, primary care physicians, and allied healthcare professionals.
LASAACI 2022 Fall Symposium Learning Objectives
At the conclusion of the conference, participants should be able to:
- Analyze and discriminate between the salient clinicopathologic features of Eosinophilic Esophagitis, Gastritis and Gastroenteritis
- Choose an appropriate therapeutic modality for single or multisegment Eosinophil-associated Gastrointestinal disorders (EGID)
- Judge the alternate diagnoses to an EGID
- Judge an appropriate clinicopathologic endpoint for therapy in EoE
- Identify the appropriate therapeutic option for an EoE patient
- Critique the clinicopathologic severity of EoE
- Describe the rationale for genetic testing in hereditary alpha tryptasemia
- Describe the clinical characteristics of patients with hereditary alpha tryptasemia
- Describe the differential diagnosis in patients being worked up for mast cell disorders
- Compare AERD to other forms of chronic sinusitis, asthma, and NSAID reactivity.
- Evaluate strategies for the treatment of patients with AERD based on guidelines and recent clinical data.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Los Angeles Society of Allergy, Asthma and Clinical Immunology (LASAACI). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 4 Contact Hours.
Current guidelines state that participants in continuing medical education activities should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty members have completed conflict of interest declarations and those potential conflicts will be listed in the course syllabus.
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers). For more information, visit www.accme.org.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
In order to receive credit, participants must sign in to the ACAAI College Learning Connection (CLC) at https://education.acaai.org, review the CME information, complete the evaluation and download their certificate. Per the American Medical Association (AMA), only physicians may receive a CME certificate. Other healthcare professionals will receive a Certificate of Attendance that they may submit to their regulatory body.
The information provided at this CME Activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
In compliance with the Americans with Disabilities Act, LASAACI requests that any participant in need of accommodation send an email to: email@example.com.
Saturday, September 24, 2022
Registration, Exhibits & Coffee Break
WELCOME AND INTRODUCTION
Dean Chiang, MD, President/Program Director
Session Moderator: Dean Chiang, MD
Eosinophilic Esophagitis: Diagnosis, Treatment, and Pathogenesis
Jonathan M. Spergel, MD, PhD
The American College of Allergy, Asthma & Immunology sponsored lecture: Advocacy and Regulatory Update
James M. Tracy, DO
Buffet Brunch, Exhibits, Posters
AERD: From Diagnosis to Management in the Biologic Era
Katharine M. Woessner, MD, FAAAAI
Elevated Tryptase – now what?
Andrew A. White, MD, FAAAAI, FACAAI
This activity is jointly provided by the American College of Allergy, Asthma and Immunology and the Los Angeles Society of Allergy, Asthma and Clinical Immunology.